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Objectives: We investigated how tonsillectomy during childhood may influence the distribution 
of HPV positive cancer of the tonsils in adult life using p16 as a surrogate marker for HPV 
infection. 
Methods: A total of 280 patients diagnosed with oropharyngeal squamous cell carcinoma 
(OPSCC) and known p16 status were eligible for this study. Each participant was called to obtain 
the childhood tonsillectomy history. Respondents were subgrouped by p16 status and the primary 
tumor location. Patient demographic and clinical information was analyzed for association with 
Fisher’s Exact and Wilcoxon Rank Sum tests.  Location of tumor was modeled using univariate 
(UVA) and multivariate (MVA) logistic regression with associated odds ratios and 95% 
confidence intervals.  
Results: Of the 280 patients, 115 (41%) were respondents: 104 (90.4%) were p16 positive and 11 
(9.6%) were p16 negative. For p16 positive patients, we observed a majority (93%) of intact tonsils 
This article is protected by copyright. All rights reserved.
in those with tonsil cancer, compared to 45% of intact tonsils in patients with p16 positive cancer 
elsewhere in the oropharynx (p<0.001).  MVA logistic regression showed that female gender (OR 
= 4.16, p=0.0675), prior smoking history (OR = 2.6, p=0.0367), and intact tonsils (OR = 15.2, 
p<0.0001) were associated with tonsillar OPSCC. 
Conclusion: We found that patients with p16 positive OPSCC at a non-tonsil site were much more 
likely to have had prior tonsillectomy versus those with p16 positive OPSCC arising within the 
tonsil. Nevertheless, we do not advocate tonsillectomies as a public health policy to reduce HPV-
related OPSCC. 
Keywords: Tonsil cancer, tonsillectomy, human papillomavirus (HPV), p16 
Level of Evidence: This is a retrospective observational study. 
 
Introduction  
Head and neck carcinomas account for 3.5% of all malignancies in western society, 
approximately 400,000 cases per year, and 90% of those are head and neck squamous cell 
carcinoma (HNSCC)1. The etiology of HNSCC has been shown to correlate with long term 
exposure to carcinogens, especially tobacco and alcohol abuse2,3. Although the overall incidence 
of HNSCC had declined over past decades with the decrease in tobacco smokers, the incidence 
of a subset of HNSCCs (those neoplasms associated with transcriptionally-active human 
papillomavirus (HPV) has actually increased4, leading to a significantly increased incidence of 
oropharyngeal squamous cell carcinoma (OPSCC) worldwide5. 
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The increasing incidences of these HNSCCs have been linked to oral HPV infection. In 
what has been termed a cancer “epidemic”6,7, these HPV positive cancers now account for 40-90% 
of HNSCCs arising from the oropharynx, mainly in individuals aged 40-551,2. These neoplasms 
characteristically have a non-keratinizing histology, but also can be keratinizing, basaloid, 
lymphoepithelial, or papillary and occur predominantly in the palatine tonsils or base of tongue8. 
Patients with HPV positive HNSCCs have a distinct risk factor profile that differs from those with 
HPV negative HNSCCs: the former associated with increased number of oral sexual partners and 
marijuana use, and the latter associated with measures of tobacco smoking, alcohol use, and poor 
oral hygiene9. 
The high-risk viral subtype HPV16 accounts for 90% of all HPV positive OPSCC.  High 
risk HPV has been linked to HNSCC tumorigenesis by a mechanism involving viral oncogenes E6 
and E7, responsible for the overexpression of heparanase and p16 respectively10. The extremely 
high correlation rates, as much as 90% -between p16 immunohistochemistry and more specific 
tests (such as the gold standard presence of HPV 16 E6/E7 mRNA), has allowed p16 
immunohistochemistry to emerge as a robust and practical surrogate marker for the 
transcriptionally active virus11  A series of 1,093 HNSCC cases demonstrated that the presence of 
HPV16 E6/E7 antibodies was significantly correlated with improved survival of HNSCC and 
OPSCC12,13. The recently published MARCH meta-analysis also supported these results13. 
Moreover, according to a retrospective evaluation of the IMCL-9815 study, p16 positive patients 
with OPSCC had improved overall survival (OS), locoregional control, and progression-free-
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survival (PFS) than the p16 negative patients14. Ang et al., demonstrated in a recursive-partitioning 
analysis of RTOG 0129 that the HPV status of the tumor was the major determinant of overall 
survival, followed by the number of pack-years of tobacco smoking (≤10 vs. >10) and then nodal 
stage (N0 to N2a vs. N2b to N3), for HPV-positive tumors15. For this reason, HPV status is one of 
the strongest prognostic indicators for OPSCC.  
It is interesting to speculate whether or not surgical removal of the palatine tonsils, a fairly 
routine procedure when performed in childhood, reduces the likelihood of developing HPV-related 
tonsil cancer later in life. A multiple-registry study of 3,859,967 Danish residents born between 
1920 and 1972, of whom 90,755 had tonsillectomies,  demonstrated a significant reduction in the 
incidence of tonsil cancer after tonsillectomy16, although the exact magnitude of this reduction is 
still unknown. In this study, we investigated how previous tonsillectomy, often occurring in 
childhood, impacts the distribution of HPV/p16 positive OPSCC in adults. 
Materials and Methods 
 This retrospective study was approved by the institutional review board of Washington 
University in Saint Louis.  
Eligibility and Patient Selection 
 Medical records of patients with OPSCC were retroactively accessed for patients diagnosed 
from 1996 to 2013. From a prospectively assembled database of 309 patients who received 
radiotherapy at Washington University in St. Louis, 280 candidates were identified based on 
having OPSCC and positive HPV status, using p16 positivity as a surrogate marker for HPV. Each 
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patient’s name and phone number were retrieved from the medical records for purposes of the 
interview. These candidates were subsequently contacted by telephone.  
 Of the candidates, we were successfully able to interview 115 respondents (non-response 
was due to outdated contact information or failure to respond after multiple attempts) who, upon 
giving consent to participate, were asked the following two questions:  
1. Did you have your tonsils removed at least 5 years before you were diagnosed with head 
and neck cancer?  
2. What year or how old were you when you had your tonsils removed, whichever you 
remember best? 
Patients that had a tonsillectomy along with the age at the time of surgery are presented in Figure 
1.  In four cases the patients were deceased, so the questions were posed to the answering member 
of the household (spouse, partner or sibling.)  
p16 Immunohistochemistry 
Immunohistochemistry was performed on 4 µm sections from formalin-fixed, paraffin-
embedded tissue blocks using an antibody to p16 (MTM Laboratories; monoclonal; 1:1 dilution) 
on a Ventana Benchmark LT automated immunostainer (Ventana Medical Systems, Inc., Tucson 
AZ) according to standard protocols.  Antigen retrieval, standard on the machine, utilized the 
Ventana CC1, EDTA-Tris, pH 8.0 solution. A known p16 expressing OPSCC or ovarian papillary 
serous carcinoma case was used as a positive control with each run.  
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 Cases were reviewed independently by the study pathologist (JSL) without knowledge of 
the other features of the cases and strong P16 immunopositivity in over 75% of tumor tissue 
was considered positive. 
Study Design and Statistics 
 The primary endpoint of this retrospective cohort study was to assess for a potential 
association between OPSCC distribution, p16 status, location of malignancy, and history of prior 
tonsillectomy. Patients were grouped according to tumor location (tonsil vs. non-tonsil cancer) and 
p16 status. Association with prior tonsillectomy and all patient demographic and clinical variables; 
including tumor location and p16 status, was assessed via Fisher’s Exact Test or Wilcoxon Rank 
Sum test where appropriate.  Univariate logistic regression (UVA) was implemented to model 
tumor location by patient age at diagnosis, sex, race, history of smoking, and TNM prognostic 
stage. Statistical significance was assessed via Wald’s Chi-Square test statistic with p-values < 
0.05 deemed statistically significant.  TNM staging information was retroactively assessed and 
patients assigned prognostic staging categories per AJCC 7th Edition cancer staging guidelines17. 
Multivariate logistic analysis (MVA) was performed on all univariately significant variables (p < 
0.1) utilizing stepwise model building. Odds Ratios, p-values, and 95% Wald confidence limits 
were calculated for all UVA and MVA analyses. 
Results 
 From 280 eligible candidates, 115 patients with a history of OPSCC were successfully 
interviewed yielding a response rate of 41%. Failures to response were most often due to non-
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current phone information (e.g. disconnected numbers) or candidates and widowed family 
members declining participation.  
 Aggregate patient characteristics and tests for association by tumor location are shown in 
Table 1. Prior tonsillectomy was performed in 32 (27.8%) of patients, and was significantly (p < 
0.0001) associated with tumor location.  Of patients with prior tonsillectomy 12.5% had palatine 
tonsil tumors while the other 87.5% had non-tonsil tumors.  Approximately half (49.6%) of all 
patients had prior smoking history. A Statistically significant relationship existed between tumor 
location and smoking status (p = 0.0249), with 59.7% of tonsil patients having smoking history 
compared to 37.7% of non-tonsil patients having prior smoking history. In order to further analyze 
patients with smoking history, we implemented as subgroup analysis for patients with a smoking 
history (Table 2). Among prior and current smokers, there was no significant difference in age of 
diagnosis, mean pack-years, sex, race, p16 status, or prognostic stage grouping between tonsil and 
non-tonsil patients.  Prior tonsillectomy remained significant in this subgroup analysis as 25% 
patients with prior tonsillectomy had tonsil tumors, while 75% had non-tonsil tumors.   
 Patients were predominantly HPV positive, with 104 (90%) having p16 positive tumors 
and 11 (10%) having p16 negative tumors. Within the p16 positive group, there were 55 (53%) 
patients with tonsil tumors, and 49 (47%) patients with non-tonsil tumors. Of the patients with 
non-tonsil tumors, 44 (90%) had tumors located at the base of tongue, with the remaining 5 (10%) 
in the following locations: floor of mouth (1), soft palate (2), oropharyngeal wall (1), and right 
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glossopharyngeal sulcus (1). Within the p16 negative group, there were 7 (64%) tonsil tumors and 
4 (36%) non-tonsil tumors.   
 We also observed statistically significant difference in tumor location among those patients 
with p16 positive tumors (Table 3).  Of the 55 patients within the p16 positive tonsil cancer group, 
only 4 patients (7.3%) had had a previous tonsillectomy (p <0.001). Conversely, within the p16+ 
non-tonsil cancer group, 27 patients (55.1%) had a previous tonsillectomy. For the p16 negative 
patients, 1 patients (14.3%) with tonsil carcinomas had had a tonsillectomy versus 2 (50%) of the 
non-tonsil carcinoma patients, which was not statistically significantly different (p=0.4909), likely 
due to small sample size (N = 10).   
 In order to model the effect of these patient clinical and demographic variables on tumor 
location we conducted UVA and MVA logistic regression.  Table 4 presents these analyses along 
with Odds Ratios (OR) and 95% confidence intervals (CI).  In UVA analysis there was significant 
association with tonsil tumor locations based on prior smoking history (OR = 2.4, p=0.0200) and 
lack of previous tonsillectomy (OR = 16.7, p < 0.0001).  Female gender was also associated (OR 
= 3.6, p=0.0603) with a higher rate of tonsil cancers and was included in MVA analysis.  In MVA 
analysis female gender (OR = 4.16, p=0.0675), prior smoking history (OR = 2.6, p=0.0367), and 
intact tonsils (OR = 15.2, p<0.0001), demonstrating that prior tonsillectomy is an independent 
predictor of tumor location after adjusting for gender and prior smoking history. 
Discussion  
 Our data suggests that prior tonsillectomy is associated with a change in the distribution of HPV-
related primary tonsil OPSCC. In patients with p16+ squamous cell carcinoma of the tonsils, we observed 
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a preponderance (91%) of intact tonsils. Conversely, in patients with p16+ squamous cell carcinoma 
elsewhere (usually the base of tongue), we observed approximately a 50% chance of tonsillectomy status. 
This suggests that tonsillectomy may confer a protective effect in developing HPV-related primary tonsil 
OPSCC.  Interestingly, a small number of patients with prior tonsillectomy still developed tonsil cancer, 
likely due to incomplete removal of the tonsil. Tonsillectomy techniques have evolved over the study 
period including microdebrider, laser, coblation, and electrocautery partial tonsillectomy and cold 
dissection, coblation, and electrocautery total tonsillectomy18. Without knowing the extent of 
tonsillectomy and amount of residual tissue, it is impossible to know if this population is indeed a 
uniform one. In our OPSCC patient cohort, multivariate analysis showed that patients without 
tonsillectomies were more than 15 times likely to be diagnosed with tonsil cancer than patients with 
tonsillectomies.   
 The growing incidence of HPV-related OPSCC has been suggested to be partially 
explained by the decline in tonsillectomy rates over the last 50 years19.  Our data supports this 
concept. The number of tonsillectomies performed on children <15 years old has declined from 
970,000 in (years) to 289,000 in 201020,21.  We hypothesize that one reason for the increased 
proportion of HPV positive to HPV negative cancers, aside from the decline in smoking rates, may 
also be partially explained by this trend. If true, we would expect a further increase in incidence 
of HPV positive tonsil cancers to continue to increase over the next few decades, as more 
individuals enter into their 40s and 50s with intact tonsils. However, future analysis would also 
need to account for the changing prevalence of oropharyngeal HPV, which could be influenced by 
trends in vaccination rates, changes in sexual practices, and novel antiviral treatments. 
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 A nation-wide study from Sweden (1970-2009) observed that tonsillectomies (N = 
225,718) were associated with reduced risk of tonsil cancers [standardized incidence ratios (SIRs) 
1+ years post-tonsillectomy = 0.31; 95% confidence interval (CI), 0.08–0.79 and 5+ years post-
tonsillectomy = 0.17; 95% CI, 0.02–0.62], but unrelated to other oropharyngeal or other head and 
neck cancers (SIRs 1+ years post-tonsillectomy = 1.61; 95% CI, 0.77–2.95 and 0.92; 95% CI, 
0.64– 1.27, respectively)22. The authors did not believe tonsillectomies should be considered as a 
secondary prevention strategy for tonsil cancers or other oropharyngeal cancers at this time. Some 
of the reasons were that: tonsillectomies did not alter risk of non-tonsil oropharyngeal cancers, and 
the mortality due to tonsillectomy outnumbers the incidence of oropharynx cancers. Other 
obstacles were inadequate risk stratification for the identification of high-risk individuals, 
inadequate identification and location of premalignant lesions, and lack of low-morbidity, cost-
effective treatments for premalignant lesions22. 
 The study from Sweden and this study raise a number of important questions. Do 
tonsillectomies decrease the incidence of tonsil cancer, the distribution of tonsil cancer or both? If 
the development of HPV-related tonsil cancer requires both tonsillar tissue and HPV exposure, 
consequently the complete removal of the tonsillar tissue (total, not partial, tonsillectomy) should 
result in a decreased incidence HPV-related tonsil cancer and altered distribution of HPV-related 
OPSCC, which is consistent with the observations of the Swedish study and our study, 
respectively. However, total tonsillectomies are unlikely to affect the incidence of non-tonsil HPV-
related OPSCC and unlikely reduce the overall incidence of OPSCC. For this reason, 
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tonsillectomies as a public health policy to reduce HPV-related OPSCC is flawed. Furthermore, 
tonsillectomy is an invasive surgical procedure that carries risks.  
 Vaccination against high-risk serotypes of HPV has been implemented nationally in 
Denmark and Australia and has been shown to be a cost-effective preventative intervention23.  
However, the incidence of OPSCC in Eastern Denmark has continued to rise with 62% of cases 
including HPV+, implying that the effects still remain to take effect and that there still exists a 
high HPV prevalence24.  We continue to recommend use of vaccination against HPV as well as 
public health efforts towards patient sexual education, smoking cessation, and alcohol abuse 
control in order to decrease the risk of OPSCC25. 
 A limitation of our current study is its retrospective nature of analysis. We used the AJCC 
7th edition for staging the tumors as this was the staging employed to classify this retrospective 
patient population. Incomplete medical records, sometimes devoid of tonsillectomy status, were 
partially circumvented by the telephone interview. Our inability to successfully contact a majority 
of eligible patients could contribute to a selection bias, particularly one which underrepresents the 
deceased, those without a phone or who changed phone numbers. No educational resources were 
provided to participants during the phone interview, so we cannot eliminate potential self-reporting 
errors of tonsillectomy status. Furthermore, due to a much smaller pool of p16 negative patients, 
our study is unable to draw conclusions regarding tonsillectomy and HPV negative tonsil cancers. 
Given the higher mortality associated with HPV negative OPSCC, p16 negative patients were 
more likely to be deceased and thus unable to be contacted and included in this study.  
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Conclusions 
 We found that patients with p16 positive OPSCC at a non-tonsil site were much more likely 
to have had prior tonsillectomy versus those arising within the tonsil. Nevertheless, we do not 
advocate tonsillectomies as a public health policy to reduce HPV-related OPSCC. 
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Table 1: Patient Demographics 
Patient Characteristic All Patients Tonsil Tumors Non-Tonsil Tumors P-Value 
N 115 62 53   
Location of Tumor [N (%)] 
   
  
Tonsil 62 (53.9%) 62 (100%) 
 
  
Base of Tongue 47 (40.9%) 
 
47 (88.7%)   
Other 6 (5.2%) 
 
6 (11.3%)   
Sex [N (%)]       0.0834* 
Male 101 (87.8%) 51 (82.3%) 50 (94.3%)   
Female 14 (12.2%) 11 (17.7%) 3 (5.7%)   
Race [N (%)] 
   
0.5094* 
Black 10 (8.7%) 4 (6.5%) 6 (11.3%)   
White 105 (91.3%) 58 (93.5%) 47 (88.7%)   
Smoking Status [N (%)]       0.0249* 
Prior or Current Smoker 57 (49.6%) 37 (59.7%) 20 (37.7%)   
Non-Smoker 58 (50.4%) 25 (40.3%) 33 (62.3%)   
P16 Status [N (%)] 
   
0.5433* 
p16+ 104 (90.4%) 55 (88.7%) 49 (92.5%)   
p16- 11 (9.57%) 7 (11.3%) 4 (7.5%)   
Tonsillectomy Status [N (%)]       <0.0001* 
Prior tonsillectomy 32 (27.8%) 4 (6.5%) 28 (52.8%)   
Intact tonsils 83 (72.2%) 58 (93.5%) 25 (47.2%)   
Stage Grouping [N (%)] 
   
0.2608* 




Stage I 2 (1.74%) 1 (1.6%) 1 (1.9%)   
Stage II 5 (4.35%) 2 (3.2%) 3 (5.7%)   
Stage III 12 (10.4%) 6 (9.7%) 6 (11.3%)   
Stage IVA 91 (79.1%) 48 (77.4%) 43 (81.1%)   
Stage IVB 5 (4.4%) 5 (8.1%) 0 (0%)   
Age at Diagnosis (mean ± SD) 56.2 ± 9.3 55.2 ± 9.9 57.5 ± 8.4 0.1427** 
Smoking Pack-Years (mean ± SD) 16.2 ± 21.8 18.3 ± 22.3 13.9 ± 21.1 0.1138** 
*P-value calculated using Fisher's Exact Test 
   
**P-value calculated using Wilcoxon Rank Sum Test 
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Table 2: Patient Age and Pack Years for Patients with Smoking History 
Patient Characteristic All Patients Tonsil Tumors Non-Tonsil Tumors P-Value 
N 57 37 20   
Location of Tumor [N (%)] 
   
  
Tonsil 37 (64.9%) 37 (100%) 
 
  
Base of Tongue 17 (29.8%) 
 
17 (85.0%)   
Other 3 (5.3%) 
 
3 (15.0%)   
Sex [N (%)]       0.2862* 
Male 4 (7.0%) 4 (10.8%) 0 (0%)   
Female 53 (93.0%) 33 (89.2%) 20 (100%)   
Race [N (%)] 
   
0.6542* 
Black 6 (10.5%) 3 (8.1%) 3 (15.0%)   
White 51 (89.47%) 34 (91.9%) 17 (85.0%)   
P16 Status [N (%)]       0.9949* 
p16+ 47 (82.5%) 30 (81.1%) 17 (85.0%)   
p16- 10 (17.5%) 7 (18.9%) 3 (15.0%)   
Tonsillectomy Status [N (%)] 
   
0.0020* 
Prior tonsillectomy 12 (21.1%) 3 (8.1%) 9 (45.0%)   
Intact tonsils 45 (78.9%) 34 (91.9%) 11 (55.0%)   
Stage Grouping [N (%)]       0.4419* 
Stage I 0 (0.0%) 0 (0.0%) 0 (0.0%)   
Stage II 4 (7.0%) 2 (5.4%) 2 (10.0%)   
Stage III 6 (10.5%) 3 (8.1%) 3 (15.0%)   
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Stage IVA 43 (75.5%) 28 (75.7%) 15 (75.0%)   
Stage IVB 4 (7.0%) 4 (10.8%) 0 (0.0%)   
Age at Diagnosis (mean ± SD) 56.7 ± 9.7 55.1 ± 9.9 59.6 ± 8.7 0.1193** 
Smoking Pack-Years (mean ± SD) 32.8 ± 20.3 30.6 ± 21.4 36.8 ± 18.1 0.1053** 
*P-value calculated using Fisher's Exact Test 
   
**P-value calculated using Wilcoxon Rank Sum Test 
   















Table 3: Tonsillectomy Effect on Tumor Location for P16+ Patients 
HPV Status Patient Characteristic Tonsil Tumors Non-Tonsil Tumors P-Value 
  N 55 49   
P16+ Tonsillectomy Status [N (%)]     <0.0001* 
N = 104 Prior tonsillectomy 4 (7.3%) 27 (55.1%)   
  Intact tonsils 51 (92.73%) 22 (44.9%)   
*P-value calculated using Fisher's Exact Test 
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Table 4: Univariate and Multivariate Logistic Regression of Patients with Tonsil Tumors 
Parameter UVA OR UVA 95% CI P* MVA OR MVA 95% CI P* 
Gender (Female) 3.57 (0.946 - 13.699) 0.0603 4.16 (0.902 - 19.138) 0.0675 
Race (White) 1.85 (0.493 - 6.946) 0.3614 
  
  
Prior Smoker 2.44 (1.151 - 5.181) 0.02 2.61 (1.061 - 6.408) 0.0367 
P16+ 0.64 (0.177 - 2.324) 0.499 
  
  
Intact tonsils 16.67 (5.154 - 50.000) <0.0001 15.16 (4.623 - 49.691) <0.0001 
Early Stage (I or II) 0.62 (0.133 - 2.916) 0.5476 
  
  
Age at Diagnosis 0.97 (0.935 - 1.014) 0.1909       
Smoking Pack-Years 1.01  (0.992 - 1.027) 0.2837       











1. Histogram for the range of ages at tonsillectomy for the 32 patients with prior 
tonsillectomy. 
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